Skip to main content

Advertisement

SpringerLink
Log in

New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy

  • Review
  • Published:
Journal of Zhejiang University SCIENCE B Aims and scope Submit manuscript

Abstract

Infection with hepatitis C virus (HCV) affects approximately 170 million people worldwide. However, no vaccine or immunoglobulin is currently available for the prevention of HCV infection. The standard of care (SOC) involving pegylated interferon-α (PEG-IFN α) plus ribavirin (RBV) for 48 weeks results in a sustained virologic response in less than 50% of patients with chronic hepatitis C genotype 1, the most prevalent type of HCV in North America and Europe. Recently, reliable in vitro culture systems have been developed for accelerating antiviral therapy research, and many new specifically targeted antiviral therapies for hepatitis C (STAT-C) and treatment strategies are being evaluated in clinical trials. These new antiviral agents are expected to improve present treatment significantly and may potentially shorten treatment duration. The aim of this review is to summarize the current developments in new anti-HCV drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ali, S., Leveque, V., Le Pogam, S., Ma, H., Philipp, F., Inocencio, N., Smith, M., Alker, A., Kang, H., Najera, I., et al., 2008. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother., 52(12):4356–4369. [doi:10.1128/AAC.00444-08]

    Article  PubMed  CAS  Google Scholar 

  • Bavisotto, L., Wang, C.C., Jacobson, I.M., Marcellin, P., Zeuzem, S., Lawitz, E.J., Lunde, M., Sereni, P., O’Brien, C., Oldach, D.W., et al., 2007. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected subjects. Hepatology, 46(4):255A.

    Google Scholar 

  • Bedard, J., Nicolas, O., Bilimoria, D., L’Heureux, L., Fex, P., David, M., Chan, L., 2009. IIdentification and characterization of VCH-222, a novel potent and selective non-nucleoside HCV polymerase inhibitor. J. Hepatol., 50(S1):S340. [doi:10.1016/S0168-8278(09)60937-5]

    Article  Google Scholar 

  • Boerner, J., Ma, S., Compton, T., Lin, K., 2007. NIM811, a cyclophilin inhibitor, and NM107, an HCV polymerase inhibitor, synergistically inhibits HCV replication and suppresses the emergence of resistance in vitro. Antivir. Res., 74(3):A57. [doi:10.1016/j.antiviral.2007.01.081]

    Article  Google Scholar 

  • Brown, N.A., 2009. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues. Expert Opin. Inv. Drugs, 18(6):709–725. [doi:10.1517/13543780902854194]

    Article  CAS  Google Scholar 

  • Burton, J.R., Everson, G.T., 2009. HCV NS5B polymerase inhibitors. Clin. Liver Dis., 13(3):453–465. [doi:10.1016/j.cld.2009.05.001]

    Article  PubMed  Google Scholar 

  • Cai, Z., Zhang, C., Chang, K.S., Jiang, J., Ahn, B.C., Wakita, T., Liang, T.J., Luo, G., 2005. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J. Virol., 79(22):13963–13973. [doi:10.1128/JVI.79.22.13963-13973.2005]

    Article  PubMed  CAS  Google Scholar 

  • Carroll, S.S., Ludmerer, S., Handt, L., Koeplinger, K., Zhang, N.R., Graham, D., Davies, M.E., MacCoss, M., Hazuda, D., Olsen, D.B., 2009. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob. Agents Chemother., 53(3):926–934. [doi:10.1128/AAC.01032-08]

    Article  PubMed  CAS  Google Scholar 

  • Chatterji, U., Lim, P., Bobardt, M.D., Wieland, S., Cordek, D.G., Vuagniaux, G., Chisari, F., Cameron, C.E., Targett-Adams, P., Parkinson, T., et al., 2010. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol., 53(1):50–56. [doi:10.1016/j.jhep.2010.01.041]

    Article  PubMed  CAS  Google Scholar 

  • Chauret, N., Chagnon-Labelle, C., Diallo, M., Laquerre, J., Laterreur, J., May, S., Ste-Marie, L., 2009. Preclinical pharmacokinetic and ADME characterization of VCH-222, a novel non-nucleoside HCV NS5B polymerase inhibitor. J. Hepatol., 50(S1):S341–S342. [doi:10.1016/S0168-8278(09)60941-7]

    Article  Google Scholar 

  • Chen, K.X., Njoroge, F.G., 2009. A review of HCV protease inhibitors. Curr. Opin. Investig. Drugs, 10(8):821–837.

    PubMed  CAS  Google Scholar 

  • Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M., 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244(4902):359–362. [doi:10.1126/science.2523562]

    Article  PubMed  CAS  Google Scholar 

  • Coelmont, L., Gallay, P., Bobardt, M., Kaptein, S., Paeshuyse, J., Vliegen, I., Vuagniaux, G., Neyts, J., 2009a. In vitro anti-hepatitis C virus (HCV) activities and resistance profile of Debio 025, a non-immunosuppressive cyclophilin binding molecule. Antivir. Res., 82(2):A20. [doi: 10.1016/j.antiviral.2009.02.024]

    Article  Google Scholar 

  • Coelmont, L., Gallay, P., Bobardt, M., Kaptein, S., Paeshuyse, J., Vliegen, I., Vuagniaux, G., Neyts, J., 2009b. Particular in vitro anti-HCV activities and resistance profile of the cyclophilin inhibitor Debio 025. J. Hepatol., 50(S1):S36. [doi:10.1016/S0168-8278(09)60090-8]

    Article  Google Scholar 

  • Coelmont, L., Hanoulle, X., Chatterji, U., Berger, C., Snoeck, J., Bobardt, M., Lim, P., Vliegen, I., Paeshuyse, J., Vuagniaux, G., et al., 2010. DEB025 (alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS ONE, 5(10):e13687. [doi:10.1371/journal.pone.0013687]

    Article  PubMed  CAS  Google Scholar 

  • Cooper, C., Lawitz, E.J., Ghali, P., Rodriguez-Torres, M., Anderson, F.H., Lee, S.S., Proulx, L., 2007. Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic hepatitis C patients: Results from a randomized, double-blind, placebo-controlled, ascending multiple dose study. Hepatology, 46(4):864A.

    Google Scholar 

  • Cooper, C., Larouche, R., Bourgault, B., Chauret, N., Proulx, L., 2009a. Safety, tolerability and pharmacokinetics of the HCV polymerase inhibitor VCH-222 following single dose administration in healthy volunteers and antiviral activity in HCV-infected individuals. J. Hepatol., 50(S1): S342. [doi:10.1016/S0168-8278(09)60942-9]

    Article  Google Scholar 

  • Cooper, C., Lawitz, E.J., Ghali, P., Rodriguez-Torres, M., Anderson, F.H., Lee, S.S., Bedard, J., Chauret, N., Thibert, R., Boivin, I., et al., 2009b. Evaluation of VCH-759 monotherapy in hepatitis C infection. J. Hepatol., 51(1): 39–46. [doi:10.1016/j.jhep.2009.03.015]

    Article  PubMed  CAS  Google Scholar 

  • Cretton-Scott, E., Perigaud, C., Peyrottes, S., Licklider, L., Camire, M., Larsson, M., La Colla, M., Hildebrand, E., Lallos, L., Bilello, J., et al., 2008. In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication. J. Hepatol., 48(S2):S220. [doi: 10.1016/S0168-8278(08)60590-5]

    Article  Google Scholar 

  • de Bruijne, J., Weegink, C.J., Jansen, P.L.M., Reesink, H.W., 2009. New developments in the antiviral treatment of hepatitis C. Vox Sanguinis, 97(1):1–12. [doi:10.1111/j.1423-0410.2009.01187.x]

    Article  PubMed  CAS  Google Scholar 

  • Delang, L., Coelmont, L., Neyts, J., 2010. Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses, 2(4):826–866. [doi:10.3390/v2040826]

    Article  PubMed  CAS  Google Scholar 

  • Deutsch, M., Papatheodoridis, G.V., 2010. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection. Curr. Opin. Investig. Drugs, 11(8):951–963.

    PubMed  CAS  Google Scholar 

  • Feld, J.J., Hoofnagle, J.H., 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, 436(7053):967–972. [doi:10.1038/nature04082]

    Article  PubMed  CAS  Google Scholar 

  • Fischer, G., Gallay, P., Hopkins, S., 2010. Cyclophilin inhibitors for the treatment of HCV infection. Curr. Opin. Investig. Drugs, 11(8):911–918.

    PubMed  CAS  Google Scholar 

  • Flisiak, R., Feinman, S.V., Jablkowski, M., Horban, A., Kryczka, W., Halota, W., Heathcote, J.E., Mazzella, G., Vandelli, C., Liz, J.S., et al., 2008a. Efficacy and safety of increasing doses of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon α-2a in treatment naive chronic HCV patients. J. Hepatol., 48(S2):62. [doi: 10.1016/S0168-8278(08)60145-2]

    Article  Google Scholar 

  • Flisiak, R., Horban, A., Gallay, P., Bobardt, M., Selvarajah, S., Wiercinska-Drapalo, A., Siwak, E., Cielniak, I., Higersberger, J., Kierkus, J., et al., 2008b. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology, 47(3):817–826. [doi:10.1002/hep.22131]

    Article  PubMed  CAS  Google Scholar 

  • Flisiak, R., Woynarowski, M., Jablkowski, M., Halota, W., Kryczka, W., Horban, A., Czauz-Andrzejuk, A., Bialkowska, J., Pawlowska, M., Zarebska-Michaluk, D., et al., 2010. Efficacy of standard of care therapy following experimental Debio 025 treatment in patients with chronic hepatitis C. J. Hepatol., 52(S1):S291. [doi:10.1016/S0168-8278(10)60750-7]

    Article  Google Scholar 

  • Foy, E., Li, K., Sumpter, R.Jr., Loo, Y.M., Johnson, C.L., Wang, C., Fish, P.M., Yoneyama, M., Fujita, T., Lemon, S.M., et al., 2005. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. PNAS, 102(8):2986–2991. [doi:10.1073/pnas.0408707102]

    Article  PubMed  CAS  Google Scholar 

  • Franco, S., Parera, M., Aparicio, E., Clotet, B., Martinez, M.A., 2007. Genetic and catalytic efficiency structure of an HCV protease quasispecies. Hepatology, 45(4):899–910. [doi:10.1002/hep.21623]

    Article  PubMed  CAS  Google Scholar 

  • Franco, S., Clotet, B., Martinez, M.A., 2008. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals. Virus Res., 131(2):260–270. [doi:10.1016/j.virusres.2007.10.003]

    Article  PubMed  CAS  Google Scholar 

  • Fridell, R.A., Qiu, D.K., Wang, C.F., Valera, L., Gao, M., 2010. Resistance analysis of the HCV NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother., 54(9):3641–3650. [doi:10.1128/AAC.00556-10]

    Article  PubMed  CAS  Google Scholar 

  • Friebe, P., Lohmann, V., Krieger, N., Bartenschlager, R., 2001. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. J. Virol., 75(24): 12047–12057. [doi:10.1128/JVI.75.24.12047-12057.2001]

    Article  PubMed  CAS  Google Scholar 

  • Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L.Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al., 2002. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med., 347(13):975–982. [doi:10.1056/NEJMoa020047]

    Article  PubMed  CAS  Google Scholar 

  • Gaither, L.A., Borawski, J., Anderson, L.J., Balabanis, K.A., Devay, P., Joberty, G., Rau, C., Schirle, M., Bouwmeester, T., Mickanin, C., et al., 2010. Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology, 397(1):43–55. [doi:10.1016/j.virol.2009.10.043]

    Article  PubMed  CAS  Google Scholar 

  • Galat, A., 2004. Function-dependent clustering of orthologues and paralogues of cyclophilins. Prot. Struct. Funct. Bioinf., 56(4):808–820. [doi:10.1002/prot.20156]

    Article  CAS  Google Scholar 

  • Gane, E., Foster, G.R., Cianciara, J., Stedman, C., Ryder, S., Buti, M., Clark, E., Tait, D., 2010a. Antiviral activity, pharmacokinetics, and tolerability of AZD7295, a novel NS5A inhibitor, in a placebo-controlled multiple ascending dose study in HCV genotype 1 and 3 patients. J. Hepatol., 52(S1):S464. [doi:10.1016/S0168-8278(10) 61194-4]

    Article  Google Scholar 

  • Gane, E., Roberts, S., Stedman, C., Angus, P., Ritchie, B., Elston, R., Ipe, D., Morcos, P., Baher, L., Najera, I., et al., 2010b. Early on-treatment responses during pegylated IFN plus ribavirin are increased following 13 days of combination nucleoside polymerase (RG7128) and protease (RG7227) inhibitor therapy (INFORM-1). J. Hepatol., 52(S1):S291–S292. [doi:10.1016/S0168-8278(10) 60751-9]

    Article  Google Scholar 

  • Gane, E.J., Roberts, S.K., Stedman, C.A., Angus, P.W., Ritchie, B., Elston, R., Ipe, D., Morcos, P.N., Baher, L., Najera, I., et al., 2010c. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet, 376(9751):1467–1475. [doi:10.1016/S0140-6736(10)61384-0]

    Article  PubMed  CAS  Google Scholar 

  • Gane, E., Rouzier, R., Stedman, C., Wiercinska-Drapalo, A., Horban, A., Chang, L., Zhang, Y., Sampeur, P., Najera, I., Shulman, N., et al., 2010d. Ritonavir boosting of low dose RG7227/ITMN-191, HCV NS3/4A protease inhibitor, results in robust reduction in HCV RNA at lower exposures than provided by unboosted regimens. J. Hepatol., 52(S1):S16–S17. [doi:10.1016/S0168-8278(10)60039-6]

    Google Scholar 

  • Gane, E.J., Rodriguez-Torres, M., Nelson, D.E., Jacobson, I.M., McHutchison, J.G., Duca, A., Hyland, R., Hill, G., Albanis, E., Symonds, W.T., et al., 2010e. Sustained virologic response (SVR) following RG7128 1500 mg BID PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders. J. Hepatol., 52(S1):S16. [doi:10.1016/S0168-8278(10)60039-6]

    Google Scholar 

  • Gao, M., Nettles, R.E., Belema, M., Snyder, L.B., Nguyen, V.N., Fridell, R.A., Serrano-Wu, M.H., Langley, D.R., Sun, J.H., O’Boyle, D.R., et al., 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature, 465(7294):96–100. [doi:10.1038/nature089960]

    Article  PubMed  CAS  Google Scholar 

  • Goto, K., Watashi, K., Murata, T., Hishiki, T., Hijikata, M., Shimotohno, K., 2006. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem. Biophys. Res. Commun., 343(3): 879–884. [doi:10.1016/j.bbrc.2006.03.059]

    Article  PubMed  CAS  Google Scholar 

  • Grakoui, A., McCourt, D.W., Wychowski, C., Feinstone, S.M., Rice, C.M., 1993. A second hepatitis C virus-encoded proteinase. PNAS, 90(22):10583–10587. [doi:10.1073/pnas.90.22.10583]

    Article  PubMed  CAS  Google Scholar 

  • Hadziyannis, S.J., Sette, H.Jr., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H.Jr., Bernstein, D., Rizzetto, M., et al., 2004. Peginterferon-α 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med., 140(5):346–355.

    PubMed  CAS  Google Scholar 

  • Hayashi, N., Takehara, T., 2006. Antiviral therapy for chronic hepatitis C: past, present, and future. J. Gastroenterol., 41(1):17–27. [doi:10.1007/s00535-005-1740-7]

    Article  PubMed  Google Scholar 

  • Herrmann, E., Kafer, A., Flisiak, R., Nicolas-Metral, V., Zeuzem, S., Crabbe, R., 2009. PK-PD modeling of viral ki netics during treatment with Debio-025 plus pegylated interferon α-2a in treatment-naive HCV patients. J. Hepatol., 50(S1):S344. [doi:10.1016/S0168-8278(09)60948-X]

    Article  Google Scholar 

  • Hezode, C., Forestier, N., Dusheiko, G., Ferenci, P., Pol, S., Goeser, T., Bronowicki, J.P., Bourliere, M., Gharakhanian, S., Bengtsson, L., et al., 2009. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med., 360(18):1839–1850. [doi:10.1056/NEJMoa0807650]

    Article  PubMed  CAS  Google Scholar 

  • Hopkins, S., Huang, Z.H., Scribner, A., Peel, M., 2009a. Antiviral activity of the non-immunosuppressive cyclophilin inhibitor SCY-635 in combination with investigational and approved anti-HCV agents. Hepatology, 50(4): 1042A.

    Google Scholar 

  • Hopkins, S., Heuman, D., Gavis, E., Lalezari, J., Glutzer, E., DiMassimo, B., Rusnak, P., Wring, S., Smitley, C., Ribeill, Y., 2009b. Safety, plasma pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection. J. Hepatol., 50(S1): S36. [doi:10.1016/S0168-8278(09)60091-X]

    Article  Google Scholar 

  • Hopkins, S., Scorneaux, B., Huang, Z.H., Murray, M.G., Wring, S., Smitley, C., Harris, R., Erdmann, F., Fischer, G., Ribeill, Y., 2010. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob. Agents Chemother., 54(2):660–672. [doi:10.1128/AAC.00660-09]

    Article  PubMed  CAS  Google Scholar 

  • Horban, A., Berak, H., Kolakowska-Rzadzka, A., Patel, H., Flisiak, R., Crabbe, R., Liz, J.S., Heathcote, J.E., 2010. Sustained virological response after 4-week treatment with Debio 025 monotherapy or coadministered with PEG-IFN α-2a in HCV genotype 1 and 3 patients. J. Hepatol., 52(S1):S294. [doi:10.1016/S0168-8278(10)60757-X]

    Article  Google Scholar 

  • Houck, D.R., Hopkins, S., 2006. Preclinical evaluation of SCY-635, a cyclophilin inhibitor with potent anti-HCV activity. Hepatology, 44(S1):534A–535A.

    Google Scholar 

  • Houghton, M., Abrignani, S., 2005. Prospects for a vaccine against the hepatitis C virus. Nature, 436(7053):961–966. [doi:10.1038/nature04081]

    Article  PubMed  CAS  Google Scholar 

  • Inoue, K., Sekiyama, K., Yamada, M., Watanabe, T., Yasuda, H., Yoshiba, M., 2003. Combined interferon α-2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J. Gastroenterol., 38(6):567–572. [doi:10.1007/s00535-002-1104-5]

    PubMed  CAS  Google Scholar 

  • Inoue, K., Umehara, T., Ruegg, U.T., Yasui, F., Watanabe, T., Yasuda, H., Dumont, J.M., Scalfaro, P., Yoshiba, M., Kohara, M., 2007. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology, 45(4):921–928. [doi:10.1002/hep.21587]

    Article  PubMed  CAS  Google Scholar 

  • Jacobson, I., Pockros, P., Lalezari, J., Lawitz, E., Rodriguez-Torres, M., DeJesus, E., Haas, F., Martorell, C., Pruitt, R., Durham, K., et al., 2009. Antiviral activity of Filibuvir in combination with pegylated interferon α-2a and Ribavirin for 28 days in treatment naive patients chronically infected with HCV genotype 1. J. Hepatol., 50(S1): S382–S383. [doi:10.1016/S0168-8278(09)61054-0]

    Article  Google Scholar 

  • Jacobson, I., Pockros, P.J., Lalezari, J., Lawitz, E., Rodriguez-Torres, M., DeJesus, E., Haas, F., Martorell, C., Pruitt, R., Purohit, V., et al., 2010. Virologic response rates following 4 weeks of Filibuvir in combination with pegylated interferon alfa-2a and Ribavirin in chronically-infected HCV genotype-1 patients. J. Hepatol., 52(S1): S465. [doi:10.1016/S0168-8278(10)61197-X]

    Google Scholar 

  • Karakama, Y., Sakamoto, N., Itsui, Y., Nakagawa, M., Tasaka-Fujita, M., Nishimura-Sakurai, Y., Kakinuma, S., Oooka, M., Azuma, S., Tsuchiya, K., et al., 2010. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. Antimicrob. Agents Chemother., 54(8):3179–3186. [doi:10.1128/AAC.00113-10]

    Article  PubMed  CAS  Google Scholar 

  • Ke, J., Lawitz, E., Rozier, R., Marbury, T., Nguyen, N., Serra, D., Dole, K., Praestgaard, J., Huang, M., Evans, T., 2009. Safety, and tolerability of NIM 811, a novel cyclophilin inhibitor for HCV, following single and multiple ascending doses in healthy volunteers and HCV-infected patients. J. Hepatol., 50(S1):S229. [doi:10.1016/S0168-8278(09)60624-3]

    Article  Google Scholar 

  • Kirkovsky, L., Zhou, Y., Norris, D., Okamoto, E., Nolan, T.G., Bartkowski, D., Khandurina, J., Sergeeva, M., Murphy, D., Ayida, B., et al., 2007. ANA598, a novel non-nucleoside inhibitor of HCV NS5B polymerase, exhibits favorable pharmacokinetic properties in multiple preclinical species. Hepatology, 46(S1):858A.

    Google Scholar 

  • Klumpp, K., Smith, D., Brandl, M., Alfredson, T., Sarma, K., Smith, M., Najera, I., Jiang, W.R., Le Pogam, S., Leveque, V., et al., 2007. Design and characterization of R1626, a prodrug of the HCV replication inhibitor R1479 (4′-azidocytidine) with enhanced oral bioavailability. Antivir. Res., 74(3):A35. [doi:10.1016/j.antiviral.2007.01.029]

    Article  Google Scholar 

  • Kolykhalov, A.A., Mihalik, K., Feinstone, S.M., Rice, C.M., 2000. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo. J. Virol., 74(4):2046–2051. [doi:10.1128/JVI.74.4.2046-2051.2000]

    Article  PubMed  CAS  Google Scholar 

  • Kukolj, G., Benhamou, Y., Manns, M.P., Bourliere, M., Pol, S., Schuchmann, M., Cartier, M., Huang, D., Lagace, L., Steinmann, G., et al., 2009. BI 201335, a potent HCV NS3 protease inhibitor, in treatment-naive and -experienced chronic HCV genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain. J. Hepatol., 50(S1):S347. [doi:10.1016/S0168-8278(09) 60956-9]

    Article  Google Scholar 

  • Kukolj, G., Bousquet, C., Dansereau, N., Do, F., Lagace, L., Llinas-Brunet, M., Marquis, M., Massariol, M.J., Maurice, R., Spickler, C., et al., 2010. Characterization of resistant mutants selected in vitro by the HCV NS3/4A protease inhibitor BI 201335. J. Hepatol., 52(S1):S295. [doi:10.1016/S0168-8278(10)60760-X]

    Article  Google Scholar 

  • Kwo, P.Y., Lawitz, E.J., McCone, J., Schiff, E.R., Vierling, J.M., Pound, D., Davis, M.N., Galati, J.S., Gordon, S.C., Ravendhran, N., et al., 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon α-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet, 376(9742):705–716. [doi:10.1016/S0140-6736(10)60934-8]

    Article  PubMed  CAS  Google Scholar 

  • Lalezari, J., Asmuth, D., Casiro, A., Vargas, H.E., Patrick, G.D., Liu, W., Pietropaolo, K., Zhou, X.J., Sullivan-Bolyai, J., Mayers, D.L., 2009. Antiviral activity, safety and pharmacokinetics of IDX184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. Hepatology, 50(6):11A–12A.

    Google Scholar 

  • Lallos, L., LaColla, M., Serra, I., Bilello, J.P., Soubasakos, M.A., Li, B., Panzo, R.J., Gillum, J.M., Bonin, A., Seifer, M., et al., 2009. Combination of IDX184, a nucleotide prodrug polymerase inhibitor, with other classes of HCV inhibitors is additive to synergistic in the HCV replicon in vitro. Hepatology, 50(4):1045A.

    Article  CAS  Google Scholar 

  • Lam, A.M., Frick, D.N., 2006. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase. J. Virol., 80(1):404–411. [doi:10.1128/JVI.80.1.404-411.2006]

    Article  PubMed  CAS  Google Scholar 

  • Larrey, D., Benhamou, Y., Lohse, A.W., Trepo, C., Moelleken, C., Bronowicki, J.P., Heim, M.H., Arasteh, K., Zarski, J.P., Bourliere, M., et al., 2009a. BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C. Hepatology, 50(4):1044A.

    Google Scholar 

  • Larrey, D., Benhamou, Y., Lohse, A.W., Trepo, C., Moelleken, C., Bronowicki, J.P., Arasteh, K., Bourliere, M., Heim, M., Enriquez, J., et al., 2009b. Safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J. Hepatol., 50(S1): S383–S384. [doi:10.1016/S0168-8278(09)61056-4]

    Article  Google Scholar 

  • Lavanchy, D., 2009. The global burden of hepatitis C. Liver Int., 29(1):74–81. [doi:10.1111/j.1478-3231.2008.01934.x]

    Article  PubMed  Google Scholar 

  • Lawitz, E., Rouzier, R., Nguyen, T., Huang, M., Ke, J., Praestgaard, J., Serra, D., Koziel, M., Evans, T., 2009. Safety and antiviral efficacy of 14 days of the cycophilin inhibitor NIM811 in combination with pegylated interferon α-2a in relapsed genotype 1 HCV infected patients. J. Hepatol., 50(S1):S379. [doi:10.1016/S0168-8278(09) 61047-3]

    Article  Google Scholar 

  • Lawitz, E.J., Marbury, T.C., Vince, B.D., Grunenberg, N., Rodriguez-Torres, M., de Micco, M.P., Tarro, J.N., Shelton, M.J., West, S., Zong, J., et al., 2010. Dose-ranging, three-day monotherapy study of the HCV NS3 protease inhibitor GS-9256. J. Hepatol., 52(S1):S466–S467. [doi:10.1016/S0168-8278(10)61199-3]

    Article  Google Scholar 

  • Lawitz, E., Rodriquez-Torres, M., Rustgi, V.K., Hassanein, T., Rahimy, M.H., Crowley, C.A., Freddo, J.L., Muir, A., McHutchison, J., 2010a. Safety and antiviral activity of ANA598 in combination with pegylated interferon α-2a plus ribavirin in treatment-naive genotype-1 chronic HCV patients. J. Hepatol., 52(S1):S467. [doi:10.1016/S0168-8278(10)61200-7]

    Article  Google Scholar 

  • Le Pogam, S., Seshaadri, A., Ewing, A., Kang, H.S., Kosaka, A., Yan, J.M., Berrey, M., Symonds, B., de la Rosa, A., Cammack, N., et al., 2010. RG7128 alone or in combination with pegylated interferon-α 2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J. Infect. Dis., 202(10):1510–1519. [doi:10.1086/656774]

    Article  PubMed  CAS  Google Scholar 

  • Lemke, C.T., Zhao, S.P., Goudreau, N., Hucke, O., Thibeault, D., Llinas-Brunet, M., White, P.W., 2010. Bound structure and biochemical mechanism of action of BI 201335, a potent, non-covalent inhibitor of HCV NS3-NS4A protease. Antivir. Res., 86(1):A20–A21. [doi:10.1016/j. antiviral.2010.02.336]

    Article  Google Scholar 

  • Levin, J., Eley, T., Pasquinelli, C., Wendelburg, P., Villegas, C., He, B., Liao, S., Jiang, H., Marbury, T., Bertz, R., et al., 2010. Safety and Pharmacokinetics of BMS-650032 Following Multiple Ascending Doses for 14 Days in Healthy Subjects. Bristol-Myers Squibb, Princeton, FL.

    Google Scholar 

  • Li, H., Tatlock, J., Linton, A., Gonzalez, J., Jewell, T., Patel, L., Ludlum, S., Drowns, M., Rahavendran, S.V., Skor, H., et al., 2009. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo [1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J. Med. Chem., 52(5):1255–1258. [doi:10.1021/jm8014537]

    Article  PubMed  CAS  Google Scholar 

  • Lin, C., Kwong, A.D., Perni, R.B., 2006. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets, 6(1):3–16. [doi:10.2174/187152606776056706]

    Article  PubMed  CAS  Google Scholar 

  • Lin, K., Kwong, A.D., Lin, C., 2004. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and α interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob. Agents Chemother., 48(12):4784–4792. [doi:10.1128/AAC.48.12.4784-4792.2004]

    Article  PubMed  CAS  Google Scholar 

  • Lin, K., Perni, R.B., Kwong, A.D., Lin, C., 2006. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob. Agents Chemother., 50(5):1813–1822. [doi:10.1128/AAC.50.5.1813-1822.2006]

    Article  PubMed  CAS  Google Scholar 

  • Lin, T.L., Lenz, O., Fanning, G., Verbinnen, T., Delouvroy, F., Scholliers, A., Vermeiren, K., Rosenquist, A., Edlund, M., Samuelsson, B., et al., 2009. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob. Agents Chemother., 53(4): 1377–1385. [doi:10.1128/AAC.01058-08]

    Article  PubMed  CAS  Google Scholar 

  • Lindenbach, B.D., Evans, M.J., Syder, A.J., Wolk, B., Tellinghuisen, T.L., Liu, C.C., Maruyamam, T., Hynes, R.O., Burton, D.R., McKeating, J.A., et al., 2005. Complete replication of hepatitis C virus in cell culture. Science, 309(5734):623–626. [doi:10.1126/science.1114016]

    Article  PubMed  CAS  Google Scholar 

  • Liu-Young, G., Kozal, M.J., 2008. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care St., 22(6):449–457. [doi:10.1089/apc.2007.0199]

    Article  Google Scholar 

  • Liverton, N.J., Carroll, S.S., Dimuzio, J., Fandozzi, C., Graham, D.J., Hazuda, D., Holloway, M.K., Ludmerer, S.W., McCauley, J.A., McIntyre, C.J., et al., 2010. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob. Agents Chemother., 54(1):305–311. [doi:10.1128/AAC.00677-09]

    Article  PubMed  CAS  Google Scholar 

  • Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., Bartenschlager, R., 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science, 285(5424):110–113. [doi:10.1126/science.285.5424.110]

    Article  PubMed  CAS  Google Scholar 

  • Lok, A.S., Gardiner, D.F., Lawitz, E., Martorell, C., Everson, G.T., Ghalib, R.H., Reindollar, R., Rustgi, V.K., Wendelburg, P., Zhu, K., et al., 2010. Combination therapy with BMS-790052 and BMS-650032 alone or with pegylated interferon and ribavirin (PEGIFN/RBV) results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. Hepatology, 52(4): 877A.

    Google Scholar 

  • Ma, S., Boerner, J.E., TiongYip, C., Weidmann, B., Ryder, N.S., Cooreman, M.P., Lin, K., 2006. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with α interferon. Antimicrob. Agents Chemother., 50(9):2976–2982. [doi: 10.1128/AAC.00310-06]

    Article  PubMed  CAS  Google Scholar 

  • Malcolm, B.A., Liu, R., Lahser, F., Agrawal, S., Belanger, B., Butkiewicz, N., Chase, R., Gheyas, F., Hart, A., Hesk, D., et al., 2006. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of α interferon in replicon cells. Antimicrob. Agents Chemother., 50(3):1013–1020. [doi:10.1128/AAC.50.3.1013-1020.2006]

    Article  PubMed  CAS  Google Scholar 

  • Manns, M., Reesink, H., Moreno, C., Berg, T., Benhamou, Y., Horsmans, Y., Dusheiko, G., Flisiak, R., Meyvisch, P., Lenz, O., et al., 2009. Opera-1 Trial: interim analysis of safety and antiviral activity of TMC435 in treatment-naive genotype 1 HCV patients. J. Hepatol., 50(S1):S7. [doi:10.1016/S0168-8278(09)60013-1]

    Article  Google Scholar 

  • Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht, J.K., 2001. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358(9286):958–965. [doi:10.1016/S0140-6736 (01)06102-5]

    Article  PubMed  CAS  Google Scholar 

  • Manns, M.P., Foster, G.R., Rockstroh, J.K., Zeuzem, S., Zoulim, F., Houghton, M., 2007. The way forward in HCV treatment—finding the right path. Nat. Rev. Drug Discov., 6(12):991–1000. [doi:10.1038/nrd2411]

    Article  PubMed  CAS  Google Scholar 

  • McCauley, J.A., McIntyre, C.J., Rudd, M.T., Nguyen, K.T., Romano, J.J., Butcher, J.W., Gilbert, K.F., Bush, K.J., Holloway, M.K., Swestock, J., et al., 2010. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4A protease inhibitor. J. Med. Chem., 53(6):2443–2463. [doi:10.1021/jm9015526]

    Article  PubMed  CAS  Google Scholar 

  • McCown, M.F., Rajyaguru, S., le Pogam, S., Ali, S., Jiang, W.R., Kang, H., Symons, J., Cammack, N., Najera, I., 2008. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother., 52(5):1604–1612. [doi:10.1128/AAC. 01317-07]

    Article  PubMed  CAS  Google Scholar 

  • McPhee, F., 2010. Identification and preclinical profile of the novel HCV NS3 protease inhibitor BMS-650032. J. Hepatol., 52(S1):S296. [doi:10.1016/S0168-8278(10)60763-5]

    Article  Google Scholar 

  • McPhee, F., Hernandez, D., Sheaffer, A., Lee, M., Falk, P., Yu, F., Zhai, G.Z., Chaniewski, S., Pasquinelli, C., 2009. Genotypic and phenotypic analysis of samples from HCV-infected subjects treated with BMS-650032 in a single ascending dose study. Hepatology, 50(S4):1048A. [doi:10.1002/hep.23307]

    Article  Google Scholar 

  • Mori, J., Hammond, J.L., Srinivasan, S., Jagannatha, S., van der Ryst, E., 2010. Genotypic characterisation of filibuvir (PF-00868554) resistance in patients receiving four weeks co-administration of filibuvir with PEGIFN/RBV (12 week analysis). J. Hepatol., 52(S1):S15. [doi:10.1016/S0168-8278(10)60037-2]

    Article  Google Scholar 

  • Moucari, R., Forestier, N., Larrey, D., Guyader, D., Couzigou, P., Benhamou, Y., Voitot, H., Vidaud, M., Seiwert, S., Bradford, B., et al., 2010. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut, 59(12):1694–1698. [doi:10.1136/gut.2010.219089]

    Article  PubMed  CAS  Google Scholar 

  • Neelakantan, S., Purohit, V.S., O’Gorman, M., Hammond, J., Tensfeldt, T.G., 2010. Exposure-response relationship of Filibuvir in HCV infected patients: application to dose selection for combination therapy. J. Hepatol., 52(S1): S119–S120. [doi:10.1016/S0168-8278(10)60288-7]

    Article  Google Scholar 

  • Nguyen, M.H., Keeffe, E.B., 2005. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin. Gastroenterol. Hepatol., 3(10):S97–S101. [doi:10.1016/S1542-3565(05)00711-1]

    Article  PubMed  CAS  Google Scholar 

  • Nicolas, O., Boivin, I., St-Denis, C., Bedard, J., 2008. Genotypic analysis of HCV NS5B variants selected from patients treated with VCH-759. J. Hepatol., 48(S2):S317. [doi:10.1016/S0168-8278(08)60846-6]

    Article  Google Scholar 

  • Ohno, T., Mizokami, M., Tibbs, C.J., Ohba, K., Suzuki, K., Wu, R.R., Nouri-Aria, K.T., Williams, R., 1994. New genotype of hepatitis C virus in South Africa. J. Med. Virol., 42(4):409–413. [doi:10.1002/jmv.1890420414]

    Article  PubMed  CAS  Google Scholar 

  • Opar, A., 2010. Excitement grows for potential revolution in hepatitis C virus treatment. Nat. Rev. Drug Discov., 9(7): 501–503. [doi:10.1038/nrd3214]

    Article  PubMed  CAS  Google Scholar 

  • Otto, M.J., Robson, R., Rodríguez, C.A., Beard, A., Symonds, W.T., Hill, G., Berrey, M.M., 2007. Pharmacokinetics, Safety, and Tolerability of R7128, a Novel Nucleoside Polymerase Inhibitor for HCV Following Single, Ascending Oral Doses in Healthy Volunteers. Pharmasset Inc., Princeton, NJ.

    Google Scholar 

  • Paeshuyse, J., Kaul, A., de Clercq, E., Rosenwirth, B., Dumont, J.M., Scalfaro, P., Bartenschlager, R., Neyts, J., 2006. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology, 43(4):761–770. [doi:10.1002/hep.21102]

    Article  PubMed  CAS  Google Scholar 

  • Patel, R., Thompson, P., Showalter, R., Appleman, J., 2010. In vitro combination studies of ANA598 with anti-HCV agents demonstrate enhanced anti-viral activity. Antivir. Res., 86(1):A41–A42. [doi:10.1016/j.antiviral.2010.02.397]

    Article  Google Scholar 

  • Pawlotsky, J.M., 2006. Therapy of hepatitis C: from empiricism to eradication. Hepatology, 43(S1):S207–S220. [doi:10.1002/hep.21064]

    Article  PubMed  CAS  Google Scholar 

  • Perni, R.B., Almquist, S.J., Byrn, R.A., Chandorkar, G., Chaturvedi, P.R., Courtney, L.F., Decker, C.J., Dinehart, K., Gates, C.A., Harbeson, S.L., et al., 2006. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother., 50(3):899–909. [doi:10.1128/AAC.50.3.899-909.2006]

    Article  PubMed  CAS  Google Scholar 

  • Pockros, P., Nelson, D., Godofsky, E., Rodriguez-Torres, M., Everson, G.T., Fried, M.W., Ghalib, R., Harrison, S., Nyberg, L., Shiffman, M.L., et al., 2008a. High relapse rate seen at week 72 for patients treated with R1626 combination therapy. Hepatology, 48(4):1349–1350. [doi:10.1002/hep.22593]

    Article  PubMed  Google Scholar 

  • Pockros, P.J., Nelson, D., Godofsky, E., Rodriguez-Torres, M., Everson, G.T., Fried, M.W., Ghalib, R., Harrison, S., Nyberg, L., Shiffman, M.L., et al., 2008b. R1626 plus peginterferon α-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology, 48(2):385–397. [doi:10.1002/hep.22357]

    Article  PubMed  CAS  Google Scholar 

  • Pol, S., Everson, G., Ghalib, R., Rustgi, V., Martorell, C., Tatum, H.A., Lim, J., Hezode, C., Diva, U., Yin, P.D., et al., 2010. Once-daily NS5A inhibitor (BMS-790052) plus peginterferon α-2a and Ribavirin produces high rates of extended rapid virologic response in treatment-naive HCV-genotype 1 subjects: phase 2a trial. J. Hepatol., 52(S1):S462. [doi:10.1016/S0168-8278(10)61190-7]

    Article  Google Scholar 

  • Rahimy, M.H., Crowley, C.A., Freddo, J.L., Sergeeva, M.V., Golec, B., 2008. Results of a phase I safety, tolerability and pharmacokinetic study of ANA598, a non-nucleoside NS5B polymerase inhibitor, in healthy volunteers. Hepatology, 48(4):1026A.

    Google Scholar 

  • Reddy, R., Rodriguez-Torres, M., Gane, E., Robson, R., Lalezari, J., Everson, G.T., Dejesus, E., McHutchison, J.G., Vargas, H.E., Beard, A., et al., 2007. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology, 46(4):862A–863A.

    Google Scholar 

  • Reesink, H.W., Fanning, G.C., Farha, K.A., Weegink, C., van Vliet, A., van’t Klooster, G., Lenz, O., Aharchi, F., Marien, K., van Remoortere, P., et al., 2010. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology, 138(3):913–921. [doi:10.1053/j.gastro.2009.10.033]

    Article  PubMed  CAS  Google Scholar 

  • Reiser, M., Timm, J., 2009. Serine protease inhibitors as anti-hepatitis C virus agents. Expert Rev. Anti.-Infect. Ther., 7(5):537–547. [doi:10.1586/eri.09.30]

    Article  PubMed  CAS  Google Scholar 

  • Reiser, M., Hinrichsen, H., Benhamou, Y., Reesink, H.W., Wedemeyer, H., Avendano, C., Riba, N., Yong, C.L., Nehmiz, G., Steinmann, G.G., 2005. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology, 41(4): 832–835. [doi:10.1002/hep.20612]

    Article  PubMed  CAS  Google Scholar 

  • Roberts, S.K., Cooksley, G., Dore, G.J., Robson, R., Shaw, D., Berns, H., Hill, G., Klumpp, K., Najera, I., Washington, C., 2008. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology, 48(2):398–406. [doi:10.1002/hep.22321]

    Article  PubMed  CAS  Google Scholar 

  • Salmon-Ceron, D., Lewden, C., Morlat, P., Bevilacqua, S., Jougla, E., Bonnet, F., Heripret, L., Costagliola, D., May, T., Chene, G., 2005. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J. Hepatol., 42(6):799–805. [doi:10.1016/j.jhep.2005.01.022]

    Article  PubMed  CAS  Google Scholar 

  • Sarrazin, C., Rouzier, R., Wagner, F., Forestier, N., Larrey, D., Gupta, S.K., Hussain, M., Shah, A., Cutler, D., Zhang, J., et al., 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon α-2b for genotype 1 nonresponders. Gastroenterology, 132(4):1270–1278. [doi:10.1053/j.gastro.2007.01.041]

    Article  PubMed  CAS  Google Scholar 

  • Schiff, E., Poordad, F.F., Jacobson, I.M., Flamm, S.L., Bacon, B.R., Lawitz, E.J., Gordon, S.R., McHutchison, J.G., Ghalib, R., Poynard, T., et al., 2008. Role of interferon response during RE-Treatment of null responders with boceprevir combination therapy: results of phase II trial. Gastroenterology, 134(4):A755. [doi:10.1016/S0016-5085(08)63527-1]

    Article  Google Scholar 

  • Schmitz, U., Tan, S.L., 2008. NS5A—from obscurity to new target for HCV therapy. Recent Pat. Anti-Infect. Drug Discov., 3(2):77–92. [doi:10.2174/157489108784746597]

    Article  CAS  Google Scholar 

  • Seth, R.B., Sun, L., Chen, Z.J., 2006. Antiviral innate immunity pathways. Cell Res., 16(2):141–147. [doi:10.1038/sj.cr.7310019]

    Article  PubMed  CAS  Google Scholar 

  • Shepard, C.W., Finelli, L., Alter, M.J., 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis., 5(9):558–567. [doi:10.1016/S1473-3099(05)70216-4]

    Article  PubMed  Google Scholar 

  • Shi, S.T., Herlihy, K.J., Graham, J.P., Nonomiya, J., Rahavendran, S.V., Skor, H., Irvine, R., Binford, S., Tatlock, J., Li, H., et al., 2009. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother., 53(6):2544–2552. [doi: 10.1128/AAC.01599-08]

    Article  PubMed  CAS  Google Scholar 

  • Shih, I.H., Vliegen, I., Peng, B., Yang, H., Paeshuyse, J., Purstinger, G., Fenaux, M., Mabery, E., Bahador, G., Lehman, L.S., et al., 2007. Mechanistic characterization of GS-9190, a novel non-nucleoside inhibitor of HCV NS5B polymerase with potent antiviral activity and a unique mechanism of action. Hepatology, 46(4):859A.

    Google Scholar 

  • Simmonds, P., 2004. Genetic diversity and evolution of hepatitis C virus—15 years on. J. Gen. Virol., 85(11):3173–3188. [doi:10.1099/vir.0.80401-0]

    Article  PubMed  CAS  Google Scholar 

  • Stauber, K., Marlor, C.W., Mushtaq, G., Gadhachanda, V., Pais, G., Hashimoto, A., Phadke, A., Huang, M., Deshpande, M., 2010. Characterization of the hepatoselective distribution of ACH-1625, a potent, clinical stage HCV NS3 protease inhibitor. J. Hepatol., 52(S1):S299. [doi:10.1016/S0168-8278(10)60772-6]

    Article  Google Scholar 

  • Susan, H., 2010. Gilead’s Investigational Hepatitis C Compounds GS 9190 and GS 9256 in Combination with Standard of Care Therapies Achieve Substantial Viral Suppression in Phase II Study. Available from http://www.gilead.com/pr_1489408 [Accessed on Nov. 20, 2011]

  • Tang, H., Grise, H., 2009. Cellular and molecular biology of HCV infection and hepatitis. Clin. Sci., 117(2):49–65. [doi:10.1042/CS20080631]

    Article  PubMed  CAS  Google Scholar 

  • Tellinghuisen, T.L., Foss, K.L., 2008. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog., 4(3):e1000032. [doi:10.1371/journal.ppat.1000032]

    Article  PubMed  CAS  Google Scholar 

  • Thompson, P.A., Patel, R., Showalter, R.E., Li, C., Applemon, J.R., Steffy, K., 2008. In vitro studies demonstrate that combinations of antiviral agents that include HCV polymerase inhibitor ANA598 have the potential to overcome viral resistance. Hepatology, 48(4):1164A.

    Google Scholar 

  • Thompson, P., Patel, R., Steffy, K., Appleman, J., 2009. Preclinical studies of ANA598 combined with other anti-HCV agents demonstrate potential of combination treatment. J. Hepatol., 50(S1):S37. [doi:10.1016/S0168-8278(09) 60092-1]

    Article  Google Scholar 

  • Thompson, P., Showalter, R., Patel, R., Appleman, J., 2010a. In vitro combination of ANA598 with other anti-HCV agents can eliminate the emergence of resistant colonies. Antivir. Res., 86(1):A48. [doi:10.1016/j.antiviral.2010.02.415]

    Article  Google Scholar 

  • Thompson, P.A., Showalter, R.E., Patel, R.A., Appleman, J.R., 2010b. Enhanced in vitro antiviral activity of ANA598 in combination with other anti-HCV Agents support combination treatment. J. Hepatol., 52(S1):S262. [doi:10.1016/S0168-8278(10)60675-7]

    Article  Google Scholar 

  • Tong, X., Arasappan, A., Bennett, F., Chase, R., Feld, B., Guo, Z., Hart, A., Madison, V., Malcolm, B., Pichardo, J., et al., 2010. Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease. Antimicrob. Agents Chemother., 54(6):2365–2370. [doi:10.1128/AAC.00135-10]

    Article  PubMed  CAS  Google Scholar 

  • Troke, P., Lewis, M., Simpson, P., van der Ryst, E., Hammond, J., Craig, C., Perros, M., Westby, M., 2009. Genotypic characterisation of HCV NS5B following 8-day monotherapy with the polymerase inhibitor PF-00868554 in HCV-infected subjects. J. Hepatol., 50(S1):S351. [doi:10.1016/S0168-8278(09)60970-3]

    Article  Google Scholar 

  • Vliegen, I., Paeshuyse, J., Marbery, E., Peng, B., Shih, H., Lehman, L.S., Dutartre, H., Selisko, B., Canard, B., Bondy, S., et al., 2007. GS-9190, a novel substituted imidazopyridine analogue, is a potent inhibitor of hepatitis C virus replication in vitro and remains active against known drug resistant mutants. Hepatology, 46(4):855A.

    Google Scholar 

  • Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Krausslich, H.G., Mizokami, M., et al., 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med., 11(7):791–796. [doi:10.1038/nm1268]

    Article  PubMed  CAS  Google Scholar 

  • Walker, M.P., Hong, Z., 2002. HCV RNA-dependent RNA polymerase as a target for antiviral development. Cur. Opin. Pharmacol., 2(5):534–540. [doi:10.1016/S1471-4892(02)00195-9]

    Article  CAS  Google Scholar 

  • Wang, C., Sarnow, P., Siddiqui, A., 1993. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J. Virol., 67(6):3338–3344.

    PubMed  CAS  Google Scholar 

  • Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M., Shimotohno, K., 2003. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology, 38(5):1282–1288. [doi:10.1053/jhep.2003.50449]

    Article  PubMed  CAS  Google Scholar 

  • Weisberg, I.S., Jacobson, I.M., 2009. Telaprevir: hope on the horizon, getting closer. Clin. Liver Dis., 13(3):441–452. [doi:10.1016/j.cld.2009.05.009]

    Article  PubMed  Google Scholar 

  • White, P.W., Llinas-Brunet, M., Amad, M., Bethell, R.C., Bolger, G., Cordingley, M.G., Duan, J.M., Garneau, M., Lagace, L., Thibeault, D., et al., 2010a. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob. Agents Chemother., 54(11):4611–4618. [doi:10.1128/AAC.00787-10]

    Article  PubMed  CAS  Google Scholar 

  • White, P.W., Llinas-Brunet, M., Amad, M., Bolger, G., Cordingley, M.G., Duan, J., Garneau, M., Lagace, L., Thibeault, D., Kukolj, G., 2010b. Preclinical characterization of non-covalent HCV NS3/4A protease inhibitor BI 201335. J. Hepatol., 52(S1):S302. [doi:10.1016/S0168-8278(10)60779-9]

    Article  Google Scholar 

  • Wong, D.A., Tong, L.K., Lim, W., 1998. High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong. Eur. J. Epidemiol., 14(5):421–426. [doi:10.1023/A:1007400304726]

    Article  PubMed  CAS  Google Scholar 

  • Yang, C., Wang, Y., Wieman, L., Eisenberg, E., Lee, M., Murray, B., Tong, L., Ray, A., Bondy, S., Tse, W., et al., 2007. Preclinical pharmacokinetic characterization of GS-9190, a novel non-nucleoside HCV NS5B polymerase inhibitor. Hepatology, 46(4):860A–861A.

    Google Scholar 

  • Yi, M., Lemon, S.M., 2003. 3′-nontranslated RNA signals required for replication of hepatitis C virus RNA. J. Virol., 77(6):3557–3568. [doi:10.1128/JVI.77.6.3557-3568.2003]

    Article  PubMed  CAS  Google Scholar 

  • Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D.R., Wielandm, S.F., Uprichard, S.L., Wakita, T., Chisari, F.V., 2005. Robust hepatitis C virus infection in vitro. PNAS, 102(26):9294–9299. [doi:10.1073/pnas.0503596102]

    Article  PubMed  CAS  Google Scholar 

  • Zhou, X.J., Pietropaolo, K., Sullivan-Bolyai, J., Kuca, B., Liu, W., Xu, L., Belanger, B., Khan, S., Mayers, D., 2009. IDX184, a liver-targeted nucleotide HCV polymerase inhibitor: results of a first-in-man safety and pharmacokinetic study. J. Hepatol., 50(S1):S351. [doi:10.1016/S0168-8278(09)60968-5]

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Public Health Sciences, University of Hawaii, Honolulu, Hawaii, 96822, USA

    Jing Tong & Yuan-an Lu

  2. Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Institute of Traditional Chinese Medicine & Natural Products, School of Pharmaceutical Sciences, Wuhan University, Wuhan, 430071, China

    Jing Tong, You-wei Wang & Yuan-an Lu

Authors
  1. Jing Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. You-wei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yuan-an Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuan-an Lu.

Additional information

Project partially supported by the Centers for Oceans and Human Health Program of the National Institute of Environmental Health Sciences (No. P50ES012740), the National Science Foundation of USA (Nos. OCE04-32479 and OCE09-11000), and the National Mega Project on Major Drug Development of China (No. 2011ZX09401-302)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tong, J., Wang, Yw. & Lu, Ya. New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy. J. Zhejiang Univ. Sci. B 13, 56–82 (2012). https://doi.org/10.1631/jzus.B1100120

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1631/jzus.B1100120

Key words

CLC number

Search

Navigation